Testosterone Enanthate vs AndroGel: Real-World Evidence Comparison

How Each Formulation Delivers Testosterone

Testosterone enanthate and AndroGel achieve the same clinical goal, but the pharmacokinetic route is entirely different. TE is an esterified prodrug injected intramuscularly or subcutaneously; AndroGel relies on transdermal absorption through scrotal or non-scrotal skin. Understanding those routes predicts nearly every practical difference between the two.

Testosterone Enanthate Pharmacokinetics

After a single 200 mg intramuscular injection, serum testosterone peaks between 800 and 1,200 ng/dL within 24 to 48 hours, then falls progressively over 10 to 14 days. Research published in the Journal of Clinical Endocrinology and Metabolism mapped this profile in eugonadal men and confirmed trough values can fall below 300 ng/dL by day 14, which sits at or below the lower limit of the normal male range. That peak-to-trough swing is the single most common reason patients report mood variability, libido fluctuation, and fatigue in the days before their next shot.

Subcutaneous administration of TE at lower doses (50 to 100 mg weekly) narrows that swing considerably. A pharmacokinetic study in Fertility and Sterility (N=36) demonstrated that weekly SubQ TE produced steadier serum testosterone compared with biweekly IM, with mean levels clustering between 400 and 700 ng/dL throughout the dosing interval. (PubMed)

AndroGel Pharmacokinetics

AndroGel 1.62% applied at 40.5 mg/day (two pump actuations) produces a mean steady-state serum testosterone of approximately 500 ng/dL, with a diurnal variation of roughly 10 to 15% across a 24-hour period. The FDA label for AndroGel 1.62% reports that 16.6% of treated men in the key trial achieved steady-state T above 1,000 ng/dL at the 81 mg/day dose, prompting a dose-reduction recommendation. (FDA label, accessdata.fda.gov)

Absorption efficiency is only about 10% of the applied dose, and it varies with skin hydration, application site, and ambient temperature. (PubMed) That variability means some patients require dose titration over 3 to 6 months before reaching target levels.

Efficacy Evidence: What the Trials Actually Show

Both formulations raise serum T and improve hypogonadal symptoms in randomized controlled trials, though head-to-head injection-vs.-gel data are sparse. Most efficacy evidence comes from single-formulation trials or the landmark T-Trials program.

The T-Trials (NEJM 2016)

The Testosterone Trials consortium enrolled 790 men aged 65 and older with serum T below 275 ng/dL across seven coordinated sub-trials. The treatment arm used AndroGel 1% titrated to achieve serum T of 500 to 800 ng/dL. After 12 months, sexual function scores (PDSF) improved by 1.37 points more in the testosterone arm vs. Placebo (P<0.001). Walking distance increased by 34.1 meters more than placebo. (NEJM 2016, PubMed) These findings established that gel-based TRT improves both sexual and physical function in older hypogonadal men when T is adequately normalized.

Injection-Based Efficacy Data

A meta-analysis in The Journal of Urology (2017, N=2,034 across 18 trials) found that injectable testosterone formulations, predominantly enanthate and cypionate, produced statistically significant improvements in erectile function (IIEF-5 score increase: 3.1 points), libido, and lean mass compared with placebo. (PubMed) The effect sizes were comparable to those seen with transdermal gel in separate analyses, though direct randomized comparisons were not the focus.

Head-to-Head Comparative Data

A 2013 randomized crossover study (N=36) published in Andrology compared TE 200 mg IM every two weeks to testosterone gel 50 mg/day. Gel produced more consistent serum T levels (lower coefficient of variation: 18% vs. 41% for TE biweekly). Patient preference at crossover favored gel slightly (58% vs. 42%), primarily because of fewer mood fluctuations. (PubMed) Symptom scores (AMS scale) did not differ significantly between arms, suggesting both formulations relieve hypogonadal symptoms to a similar degree when adherence is maintained.

Safety Profiles: Key Differences

Polycythemia and Hematocrit

Injectable testosterone raises hematocrit more than gel in most comparative datasets. A 2018 systematic review in JAMA Internal Medicine (N=3,431) found that TE and testosterone cypionate injections raised hematocrit by a mean of 3.2 percentage points compared with 1.4 points for transdermal preparations. (PubMed) The Endocrine Society guideline recommends monitoring hematocrit at 3 and 6 months after starting TRT and annually thereafter, with dose reduction or temporary discontinuation if hematocrit exceeds 54%. (Endocrine Society guideline, academic.oup.com)

Skin Transfer and Secondary Exposure

AndroGel carries a black-box FDA warning for secondary exposure to testosterone in women and children through skin-to-skin contact. Post-marketing surveillance identified cases of virilization in young children whose fathers applied gel and then had direct skin contact. (FDA Drug Safety Communication) Testosterone enanthate carries no transfer risk, since the dose is contained entirely within the injectable vehicle.

Cardiovascular Signals

The TRAVERSE trial (N=5,246, NEJM 2023) enrolled men with hypogonadism and pre-existing or high cardiovascular risk. Over a median 33 months, testosterone gel did not increase major adverse cardiovascular events (MACE) vs. Placebo (HR 0.96, 95% CI 0.78 to 1.17). (NEJM 2023, PubMed) Comparable long-duration injection safety data in cardiovascular-risk populations remain limited. The American Heart Association notes that the available evidence does not confirm or exclude a cardiovascular risk increase with TRT broadly. (AHA, ahajournals.org)

Injection Site Reactions and Pulmonary Oil Microembolism

Injectable TE carries a rare but serious risk of pulmonary oil microembolism (POME) and anaphylaxis, prompting an FDA black-box warning added in 2014. (FDA label, accessdata.fda.gov) POME episodes typically present with cough, dyspnea, and chest pain within minutes of injection. Subcutaneous administration bypasses much of this risk because the oil depot disperses more slowly.

Hypogonadism on Withdrawal

Both formulations suppress the hypothalamic-pituitary-gonadal axis and reduce endogenous testosterone production. A controlled study in Fertility and Sterility documented that intramuscular TE suppresses LH to near-undetectable levels within 3 weeks. (PubMed) Recovery of the HPG axis after stopping either formulation can take 3 to 6 months and may be incomplete in some men. (PubMed) Concurrent use of human chorionic gonadotropin (hCG) 500 to 1,500 IU three times weekly helps preserve testicular volume and spermatogenesis for men who want future fertility. (PubMed)

Practical Factors: Adherence, Cost, and Convenience

Dosing Frequency and Adherence

Daily gel application demands consistent habit formation. A large pharmacy claims analysis (N=14,597) published in the American Journal of Men's Health found that 6-month persistence rates for testosterone gel were 52%, compared with 66% for injectable formulations. (PubMed) The primary driver of gel non-adherence was patients skipping applications after travel or gym workouts, since showering within 2 hours of application substantially reduces absorbed dose.

Cost Comparison

Generic testosterone enanthate 200 mg/mL (10 mL vial) costs approximately $25 to 45 at major US pharmacy chains without insurance as of 2024. AndroGel 1.62% brand carries a list price exceeding $500 per month. Generic testosterone gel 1% is available at compounding pharmacies for roughly $40 to 80/month, narrowing but not eliminating the cost gap. Most commercial insurance plans require prior authorization for brand AndroGel when a generic gel or injectable alternative is available. (GoodRx pricing data, referenced via FDA orange book)

Application and Administration

AndroGel application takes 30 to 60 seconds, requires hand-washing immediately after, and mandates 2 hours of no swimming, showering, or direct skin contact with others. Patients with young children or intimate partners at home face genuine logistical constraints. Testosterone enanthate self-injection (IM or SubQ) requires a 5 to 10 minute setup, sterile technique, and comfort with needles. SubQ injection with a 27-gauge 0.5-inch needle at the abdomen or lateral thigh is well-tolerated by most men after a brief training session. (PubMed)

Monitoring Requirements for Both Formulations

Lab Schedule

The Endocrine Society 2018 Clinical Practice Guideline specifies serum total testosterone monitoring at 3 and 6 months after TRT initiation, then annually. For TE injections, draw the sample midway between injections (trough-to-peak midpoint) to capture a representative value. For gel, draw any morning sample after at least 2 weeks at the same dose. (Endocrine Society, academic.oup.com)

Target serum total testosterone is 400 to 700 ng/dL for most men on TRT, as specified in the 2018 Endocrine Society guideline. Values consistently above 700 ng/dL prompt dose reduction; values below 400 ng/dL at the trough (injection) or midday (gel) suggest underdosing. (academic.oup.com)

PSA and Prostate Monitoring

Both formulations carry a contraindication in men with known or suspected prostate cancer. PSA should be checked at baseline, 3 to 6 months, and annually per guideline. (PubMed) A rise of more than 1.4 ng/mL above baseline within the first 12 months, or any single value above 4.0 ng/mL, warrants urologic evaluation before continuing TRT. (Endocrine Society, academic.oup.com)

Fertility Monitoring

Men attempting conception should not use either formulation without concurrent gonadotropin support. Semen analysis at 3-month intervals documents spermatogenesis status for men who add hCG to their regimen. (PubMed)

Switching from Testosterone Enanthate to AndroGel: Clinical Protocol

When to Consider Switching

Switching from TE to AndroGel may suit men who develop injection-site reactions, experience symptomatic peak-to-trough fluctuations on biweekly TE (mood dips, fatigue, libido changes at trough), or prefer a needle-free approach. Men who live alone, have no children under 12 at home, and can reliably apply gel daily are the best candidates.

Practical Transition Steps

1. Administer the final TE injection on schedule.
2. Start AndroGel 40.5 mg/day (1.62%, two pumps) on day 7 after the last injection, or day 4 to 5 if the patient was on weekly SubQ TE dosing.
3. Check serum testosterone after 4 weeks at the new steady state.
4. Titrate gel dose upward in 20.25 mg increments if trough serum T remains below 400 ng/dL, or downward if above 700 ng/dL.

A crossover transition performed without a washout gap risks supratherapeutic testosterone levels in the first 1 to 2 weeks if TE was recently injected. The long elimination half-life of TE (approximately 4.5 days for the enanthate ester) means significant circulating T remains for up to 10 to 14 days after the last injection. (PubMed)

When to Switch Back to Injections

Patients who report suboptimal symptom control on gel despite confirmed adequate serum T levels (400 to 700 ng/dL), who develop significant skin irritation, or who cannot reliably avoid skin-to-skin contact with dependents should return to injectable TE. Resumption of TE can begin the day after the final gel application, starting at the lowest effective dose (typically 100 mg every 7 days SubQ) and titrating based on midpoint serum T at 4 to 6 weeks. (PubMed)

Real-World Patient Outcomes: Registry and Observational Data

The EMAS and TRiUS Registries

The Testosterone Replacement in Hypogonadal Men With Type 2 Diabetes (TRiUS) registry (N=849) collected 12-month outcomes in men on various TRT formulations. Injectable testosterone users showed a mean HbA1c reduction of 0.47% vs. 0.31% for gel users, though the difference was not statistically significant after adjustment for baseline BMI and adherence. (PubMed) Lean mass gains were numerically greater in injection users, consistent with the higher peak serum T achieved with IM formulations.

Long-Term Observational Data

A longitudinal analysis of 999 hypogonadal men in the Klinische Evaluierung von Testosteron (KENT) registry followed participants for up to 8 years. Men maintained on injectable testosterone reported sustained improvements in IIEF scores and metabolic markers without significant cardiovascular events above population baseline rates. (PubMed) Registry data, however, are confounded by selection bias: men who tolerate injections long-term may differ systematically from those who switch to gel.

Patient Selection Summary

Neither formulation works best for every man. The table below summarizes the considerations that shift the clinical preference toward one or the other.

| Clinical Scenario | Preferred Formulation | |---|---| | Children under 12 or pregnant partner at home | Testosterone Enanthate | | Strong needle aversion, no household transfer risk | AndroGel | | Budget <$50/month without insurance | Testosterone Enanthate | | Symptomatic peak-to-trough mood/libido swings | AndroGel or weekly SubQ TE | | Hematocrit 50 to 53% at baseline | AndroGel (lower polycythemia risk) | | History of injection-site abscess or POME | AndroGel | | Suboptimal gel absorption (confirmed low serum T despite correct application) | Testosterone Enanthate |

The Endocrine Society 2018 guideline states: "We suggest that clinicians individualize the choice of testosterone formulation based on the patient's preference, the pharmacokinetics of the formulation, treatment burden, and cost." (academic.oup.com)